KAZIA THERAPEUTICS-SPON ADR (KZIA)
US48669G1058 - ADR
We assign a fundamental rating of 2 out of 10 to KZIA. KZIA was compared to 565 industry peers in the Biotechnology industry. KZIA has a bad profitability rating. Also its financial health evaluation is rather negative. KZIA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
KZIA had negative earnings in the past year.
KZIA had a negative operating cash flow in the past year.
KZIA had negative earnings in each of the past 5 years.
KZIA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
KZIA has a Return On Assets of -72.87%. This is in the lower half of the industry: KZIA underperforms 67.56% of its industry peers.
KZIA has a Return On Equity of -169.83%. This is in the lower half of the industry: KZIA underperforms 65.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.87% | ||
| ROE | -169.83% | ||
| ROIC | N/A |
ROA(3y)-52.36%
ROA(5y)-51.92%
ROE(3y)-109.65%
ROE(5y)-97.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KZIA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KZIA has been increased compared to 5 years ago.
KZIA has a worse debt/assets ratio than last year.
2.2 Solvency
KZIA has an Altman-Z score of 2.54. This is not the best score and indicates that KZIA is in the grey zone with still only limited risk for bankruptcy at the moment.
KZIA has a better Altman-Z score (2.54) than 73.97% of its industry peers.
A Debt/Equity ratio of 0.15 indicates that KZIA is not too dependend on debt financing.
KZIA's Debt to Equity ratio of 0.15 is on the low side compared to the rest of the industry. KZIA is outperformed by 66.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.54 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
KZIA has a Current Ratio of 1.42. This is a normal value and indicates that KZIA is financially healthy and should not expect problems in meeting its short term obligations.
KZIA's Current ratio of 1.42 is on the low side compared to the rest of the industry. KZIA is outperformed by 81.82% of its industry peers.
KZIA has a Quick Ratio of 1.42. This is a normal value and indicates that KZIA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of KZIA (1.42) is worse than 81.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
KZIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.28%, which is quite impressive.
Looking at the last year, KZIA shows a very strong growth in Revenue. The Revenue has grown by 974.29%.
The Revenue for KZIA have been decreasing by -28.31% on average. This is quite bad
EPS 1Y (TTM)34.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.14%
Revenue 1Y (TTM)974.29%
Revenue growth 3Y-30.05%
Revenue growth 5Y-28.31%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, KZIA will show a very strong growth in Earnings Per Share. The EPS will grow by 21.30% on average per year.
The Revenue is expected to grow by 385.92% on average over the next years. This is a very strong growth
EPS Next Y101%
EPS Next 2Y41.87%
EPS Next 3Y15.81%
EPS Next 5Y21.3%
Revenue Next Year95807.9%
Revenue Next 2Y2996.9%
Revenue Next 3Y397.46%
Revenue Next 5Y385.92%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
KZIA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
KZIA is valuated quite expensively with a Price/Forward Earnings ratio of 787.22.
KZIA's Price/Forward Earnings ratio is rather cheap when compared to the industry. KZIA is cheaper than 91.09% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.00, KZIA is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 787.22 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
KZIA's earnings are expected to grow with 15.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.87%
EPS Next 3Y15.81%
5. Dividend
5.1 Amount
KZIA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KAZIA THERAPEUTICS-SPON ADR
NASDAQ:KZIA (11/22/2024, 5:38:18 PM)
5.76
+0.23 (+4.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap171.61M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 787.22 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.87% | ||
| ROE | -169.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)34.28%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y101%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)974.29%
Revenue growth 3Y-30.05%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y